Jefferies Financial Group Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)

Analysts at Jefferies Financial Group started coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report issued on Wednesday, Zacks reports. The brokerage set a “strong-buy” rating on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently commented on SUPN. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an “overweight” rating in a report on Wednesday. Weiss Ratings lowered Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Piper Sandler assumed coverage on Supernus Pharmaceuticals in a research note on Wednesday. They set an “overweight” rating and a $47.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $63.50.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $28.21 on Wednesday. The company has a market capitalization of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84. Supernus Pharmaceuticals has a one year low of $26.74 and a one year high of $42.81. The company’s fifty day moving average price is $41.74 and its 200-day moving average price is $47.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). The firm had revenue of $208.60 million for the quarter, compared to analysts’ expectations of $217.56 million. Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.80) EPS. Equities research analysts expect that Supernus Pharmaceuticals will post 3.66 earnings per share for the current fiscal year.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio bought a new stake in Supernus Pharmaceuticals in the 2nd quarter worth approximately $25,000. Rockefeller Capital Management L.P. boosted its position in shares of Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares during the last quarter. Heritage Family Offices LLP bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Global Retirement Partners LLC bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at approximately $64,000. Finally, Versant Capital Management Inc boosted its position in shares of Supernus Pharmaceuticals by 47.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 482 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Key Headlines Impacting Supernus Pharmaceuticals

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $87 and maintained an “overweight” rating, signaling substantial potential upside in the firm’s view. However, the target may not reflect the completed merger or subsequent listing changes. Cantor Fitzgerald rating information
• Positive Sentiment: Recent commentary describes SUPN as potentially undervalued, citing ONAPGO’s exclusivity and the combined company’s prospects. These are valuation arguments, not company guidance. Supernus after its Indivior merger looks undervalued Supernus may be undervalued after ONAPGO exclusivity
• Positive Sentiment: One report highlights $473 million in shareholder payouts, a potentially favorable one-time return of capital. Supernus sends $473 million to shareholders
• Neutral Sentiment: Supernus completed its merger with Indivior, creating a CNS-focused biopharmaceutical company. The combination could broaden the business, but investors will assess the merged company’s prospects and integration. Supernus completes merger with Indivior
• Negative Sentiment: The merger and reported Nasdaq delisting raise uncertainty for investors holding SUPN: the shares may no longer trade as a standalone Nasdaq-listed security, limiting the relevance of older SUPN targets and comparisons. Changes after Supernus’s Nasdaq delisting and merger

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.